|View printer-friendly version|
|Wright Medical Group N.V. Highlights Significant New Product Launches at the American Orthopaedic Foot & Ankle Society (AOFAS) 2018 Annual Meeting|
Company Announces U.S. Launch of PROstep™ Minimally Invasive Surgery System
Company Initiates U.S. Commercial Distribution and Sale of AUGMENT® Injectable Bone Graft
Specifically designed for foot and ankle surgery, the PROstep system provides a minimally invasive, procedurally integrated solution that features specifically designed implants and instrumentation for percutaneous surgery of the foot. The PROstep System can be used to treat a variety of forefoot and hindfoot pathologies, including one of the most common, Hallux Valgus, commonly known as bunions, a painful foot deformity that is prevalent in approximately 23% in adults aged 18-65 years and 35.7% in elderly people aged over 65 yearsi. Compared to a traditional open surgery, the PROstep System has been shown to get patients back on their feet faster, with less pain and an improved cosmetic result. More information on PROstep can be found at www.ProstepMIS.com.
“With the PROstep Minimally Invasive Surgery approach to bunion and other foot and ankle deformities, my patients experience far less post-operative pain and experience a faster return to function much more quickly than traditional open surgery,” said Dr.
AUGMENT Injectable is the first clinically proven injectable protein therapeutic to come to the U.S. orthopaedic market offering an alternative to autograft in ankle and/or hindfoot fusion procedures, which translates into an estimated market opportunity of approximately
Wright also announced the achievement of a clinical milestone, surpassing 30,000 total ankle replacement (TAR) procedures globally since 2008. Wright offers a complete continuum of care from primary through revision TAR procedures including the INBONE™ Total Ankle System, the INFINITY™ Total Ankle System, the INVISION™ Total Ankle Revision System and the PROPHECY™ Preoperative Navigation System.
Other products to be featured at the AOFAS include:
SALVATION™ 2 Limb Reconstruction System – The SALVATION 2 Limb Reconstruction System is the first truly comprehensive product solution design to address limb salvage procedures in neuropathic patients. The system is designed to help simplify this often-complex procedure, while giving surgeons the options needed to best address these challenging cases. The external fixation system provides preassembled components, patient positioning tools and reproducible wire placement guides to streamline application and eliminate surgical steps.
INVISION™ Total Ankle Revision System with PROPHECY Preoperative Navigation – The first and only system developed specifically for total ankle revision arthroplasty with preoperative planning, the INVISION Total Ankle Revision System helps surgeons re-build bone lost through previous surgeries and provides modularity to help restore natural joint height. The introduction of INVISION with PROPHECY is an important addition to Wright’s total ankle portfolio, extending the use of the only preoperative planning system for total ankles to the entire continuum of care from primary through revision procedures.
ORTHOLOC™ Universal Anterior Ankle Fusion Plate – The Universal Anterior Ankle Fusion Plate is the latest addition to the ORTHOLOC™ Ankle Fusion Plating System, which features Wright’s innovative 3Di polyaxial locking technology. By offering multiple points of talus fixation, the option for tibio-talar-calcaneal fusion and an external lag screw targeting guide, the Universal Anterior Ankle Fusion Plate provides surgeons with a versatile, intraoperative solution for patients requiring ankle fusion.
For more information about Wright Medical’s portfolio of foot and ankle products, visit: www.totalankleinstitute.com
Internet Posting of Information
Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com. The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include, but are not limited to, statements about the performance and market acceptance of the company’s products. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, physician acceptance, endorsement, and use of company products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims; product recalls; the effects of industry, economic or political conditions outside of the company’s control; competitor activities; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended
Investors & Media:
Julie D. Dewey